Journal
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
Volume 14, Issue -, Pages 58-64Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jgar.2018.02.013
Keywords
Antimicrobial stewardship; Antifungal; New drug development; Systematic literature review
Categories
Funding
- Cidara Therapeutics
Ask authors/readers for more resources
Objectives: Rezafungin (CD101) is a novel echinocandin currently under development. The purpose of this study was to perform a systematic literature review of published evidence on rezafungin and an antimicrobial stewardship audit of real-world use of echinocandins to determine areas of unmet medical needs and potential places in therapy for rezafungin. Methods: The systematic literature review identified 8 peer-reviewed manuscripts and 19 separate abstracts. A stewardship audit was performed on hospitalised patients receiving echinocandins to better understand potential future areas of use for rezafungin. Results: Rezafungin is a cyclic hexapeptide with a lipophilic tail derived from anidulafungin, with a choline moiety at the C5 ornithine position resulting in increased in vitro and in vivo stability compared with other echinocandins. Microbiological data showed similar susceptibility and resistance development between rezafungin and other echinocandins. Rezafungin has a long half-life (80 h) and a favourable safety profile that allows for high doses (up to 400 mg) given once weekly. A phase 2 study is ongoing. The antimicrobial stewardship audit of echinocandin identified several areas of possible use for rezafungin, including patients receiving daily echinocandins for >7 days, patients who remained in the hospital to complete a full course of daily echinocandin therapy, and patients who required an echinocandin scheduled via an infusion clinic after discharge. Conclusion: Rezafungin is a novel echinocandin currently in phase 2 studies, differentiated by a long half-life that allows once-weekly dosing and a safety profile that allows higher doses. Several potential areas of use for rezafungin were identified. (C) 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Chemotherapy of Infection and Cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available